Jiangsu Asieris Pharmaceuticals Co Ltd (688176)

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. Its pipeline includes APL-1202, which is in Phase III clinical trial for the treatment of urinary system tumors; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors; APL-1706, which is in Phase III clinical trial for the treatment of urinary system tumors; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-240 and ASN-2304 for the treatment of urinary system tumors; and APL-1901 for the treatment of ER positive breast cancer. Further, the company develops APL-2302 which is in phase I of clinical trial for the treatment of ovarian cancer, breast cancer, etc.; and APL-2501, AT-018, and AT-021 which are in the preclinical research phase for the treatment of Ovarian cancer, breast cancer, and other solid tumors. Additionally, the company develops APL-1401 to treat moderately to severely active ulcerative colitis, ASN-1202 to treat free-living amebic infection, and APL-2301 for the treatment of Acinetobacter baumannii Infections. The company also offers TIMIN platform, a targeted immune regulation normalization technology platform for the development of new drugs for tumor immunotherapy and autoimmune diseases, TAIDD, a drug discovery platform that integrates physical modeling and artificial intelligence technologies, including core functional modules for target-based drug discovery, and DDC, a drug-device combination platform to deliver diagnostic or therapeutic drugs for the target site to reduce the systemic exposure of the drug. Jiangsu Yahong Meditech Co., Ltd. was founded in 2010 and is based in Shanghai, China.